Evidence map›Paper›PMID 31122738›Full record

ArticleBritish journal of anaesthesia2019

Xenon improves long-term cognitive function, reduces neuronal loss and chronic neuroinflammation, and improves survival after traumatic brain injury in mice.

Rita Campos-Pires, Tobias Hirnet, Flavia Valeo, Bee Eng Ong, Konstantin Radyushkin, Jitka Aldhoun, Joanna Saville, Christopher J Edge, Nicholas P Franks, Serge C Thal and 1 more

Open access · hybridAbstract read
In one paragraph

Article in British journal of anaesthesia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. CSF1R and IL1R1 inhibitors synergistically attenuate the early pathogenesis of traumatic brain injury in mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Rita Campos-PiresAnaesthetics, Pain Medicine and Intensive Care Section, Department of Surgery and Cancer, UK; Royal British Legion Centre for Blast Injury Studies, Department of Bioengineering, Imperial College London, UK; Charing Cross Hospital Intensive Care Unit, Critical Care Directorate, Imperial College Healthcare NHS Trust, London, UK.
Tobias HirnetDepartment of Anaesthesiology, Medical Centre of Johannes Gutenberg University, Mainz, Germany.
Flavia ValeoAnaesthetics, Pain Medicine and Intensive Care Section, Department of Surgery and Cancer, UK.
Bee Eng OngAnaesthetics, Pain Medicine and Intensive Care Section, Department of Surgery and Cancer, UK.
Konstantin RadyushkinMouse Behavioural Outcome Unit, Focus Program Translational Neurosciences, Johannes Gutenberg University, Mainz, Germany.
Jitka AldhounAnaesthetics, Pain Medicine and Intensive Care Section, Department of Surgery and Cancer, UK.
Joanna SavilleAnaesthetics, Pain Medicine and Intensive Care Section, Department of Surgery and Cancer, UK.
Christopher J EdgeDepartment of Life Sciences, Imperial College London, UK; Department of Anaesthetics, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK.
Nicholas P FranksDepartment of Life Sciences, Imperial College London, UK.
Serge C ThalDepartment of Anaesthesiology, Medical Centre of Johannes Gutenberg University, Mainz, Germany. Electronic address: thal@uni-mainz.de.
Robert DickinsonAnaesthetics, Pain Medicine and Intensive Care Section, Department of Surgery and Cancer, UK; Royal British Legion Centre for Blast Injury Studies, Department of Bioengineering, Imperial College London, UK. Electronic address: r.dickinson@imperial.ac.uk.
Imperial College London · GBUniversity Medical Center of the Johannes Gutenberg University Mainz · DEImperial College Healthcare NHS Trust · GBJohannes Gutenberg University Mainz · DERoyal Berkshire NHS Foundation Trust · GB

Funding

Medical Research Council MC_PC_13064Medical Research Council MR/N027736/1
6 · The paper itself

Abstract

backgroundXenon is a noble gas with neuroprotective properties that can improve short and long-term outcomes in young adult mice after controlled cortical impact. This follow-up study investigates the effects of xenon on very long-term outcomes and survival.

methodsC57BL/6N young adult male mice (n=72) received single controlled cortical impact or sham surgery and were treated with either xenon (75% Xe:25% O

resultsXenon treatment significantly reduced secondary injury (P<0.05), improved short-term vestibulomotor function (P<0.01), and prevented development of very late-onset traumatic brain injury (TBI)-related memory deficits. Xenon treatment reduced white matter loss in the contralateral corpus callosum and neuronal loss in the contralateral hippocampal CA1 and dentate gyrus areas at 20 months. Xenon's long-term neuroprotective effects were associated with a significant (P<0.05) reduction in neuroinflammation in multiple brain areas involved in associative memory, including reduction in reactive astrogliosis and microglial cell proliferation. Survival was improved significantly (P<0.05) in xenon-treated animals compared with untreated animals up to 12 months after injury.

conclusionsXenon treatment after TBI results in very long-term improvements in clinically relevant outcomes and survival. Our findings support the idea that xenon treatment shortly after TBI may have long-term benefits in the treatment of brain trauma patients.

Indexed as

AnimalsBrainBrain Injuries, TraumaticChronic DiseaseCognitionCognition DisordersDisease Models, AnimalFollow-Up StudiesInflammationMaleMiceMice, Inbred C57BLNeuronsNeuroprotective AgentsSurvival AnalysisXenonNeuroprotective AgentsXenongeneral anaesthesiahippocampusmemory disordersnerve degenerationneuroinflammationneuroprotectiontraumatic brain injury

Identifiers

PMID31122738
PMCPMC6676773
OpenAlexW2945580006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.